Napabucasin
CanStem111P
Phase 3 small_molecule completed
Quick answer
Napabucasin for Carcinoma, Pancreatic Ductal is a Phase 3 program (small_molecule) at Sumitomo Pharma (Suzhou) Co., with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sumitomo Pharma (Suzhou) Co.,
- Indication
- Carcinoma, Pancreatic Ductal
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed